Mallinckrodt (NYSE: MNK) reported Q4 EPS of $2.40, $0.35 better than the analyst estimate of $2.05. Revenue for the quarter came in at $804.9 million versus the consensus estimate of $772.52 million.

• As separately announced today, reached an agreement in principle for a global settlement with a broad-based group of plaintiffs that would resolve all opioid-related claims against the company and its subsidiaries, and taking actions to address near-term maturities to strengthen capital structure

For earnings history and earnings-related data on Mallinckrodt (MNK) click here.